Warren Lammert is the co-founder and Chairman of Tevard Biosciences which is developing gene therapies for genetic cardiomyopathies, Duchenne muscular dystrophy and other haplo-insufficient genetic disorders. He served as the founder and Co-CIO of Granite Point Capital, a public/private investment firm which invested in public and private investments from 2004 to 2024. Warren began his career in finance as a research associate with Fred Alger Management in New York City in 1984 and has over 35 years of investment experience as an analyst and portfolio manager. He is a graduate of Yale University and the London School of Economics where he completed an MSc in Economic History with Distinction. He is a CFA® charter holder.

Warren has worked to support new therapies in epilepsy over the last twenty-five years. He was the co-founder of Epilepsy.com and the Epilepsy Therapy Project which merged with the Epilepsy Foundation in 2013. After the merger, Warren served as chairman of the new Epilepsy Foundation for several years and as Board Member until 2019. He currently serves on the advisory board of the NYU Affiliated philanthropy Finding a Cure for Epilepsy and Seizures. In recent years, Warren has also served in board roles with companies developing new therapies for epilepsy including Biscayne Neurotherapeutics (acquired by Supernus Pharma in 2018), Engage Therapeutics (acquired by UCB in 2020), Receptor Therapeutics, and Cerebral Therapeutics where he served as board chair from 2018- 2020. Warren served on the Advisory Council of the Atlas Network from 2016 to 2022.

Warren’s interests include classical liberalism, economic history, language (Chinese and Spanish), diet and calisthenics.